So where might mAb therapeutic drug monitoring have the most value for us, going forward? Proactive testing not at the moment (e.g. NOR-DRUM-A) but plenty of opportunities still exist! 6/ @MeghnaJani #EULAR2021 @RheumNow https://t.co/W5JATFHLfx